

Robert J Fox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4437073/publications.pdf>

Version: 2024-02-01

143
papers

11,951
citations

76326

40
h-index

27406

106
g-index

146
all docs

146
docs citations

146
times ranked

11129
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining the clinical course of multiple sclerosis. <i>Neurology</i> , 2014, 83, 278-286.	1.1	2,344
2	B-Cell Depletion with Rituximab in Relapsing/Remitting Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2008, 358, 676-688.	27.0	2,107
3	Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2012, 367, 1087-1097.	27.0	1,161
4	Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. <i>Annals of Neurology</i> , 2006, 59, 478-489.	5.3	748
5	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet</i> , The, 2018, 391, 1263-1273.	13.7	684
6	Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. <i>Lancet</i> , The, 2017, 389, 1357-1366.	13.7	235
7	Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 699.	9.0	225
8	Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2018, 379, 846-855.	27.0	201
9	Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. <i>Lancet Neurology</i> , The, 2015, 14, 208-223.	10.2	188
10	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e1870-e1885.	1.1	168
11	MS disease activity in RESTORE. <i>Neurology</i> , 2014, 82, 1491-1498.	1.1	166
12	Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study. <i>JAMA Neurology</i> , 2021, 78, 558.	9.0	132
13	Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 253-265.	3.0	126
14	Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1534-1540.	3.0	116
15	Imaging correlates of axonal swelling in chronic multiple sclerosis brains. <i>Annals of Neurology</i> , 2007, 62, 219-228.	5.3	107
16	Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study. <i>Lancet Neurology</i> , The, 2018, 17, 870-884.	10.2	103
17	Serum neurofilament light as a biomarker in progressive multiple sclerosis. <i>Neurology</i> , 2020, 95, 436-444.	1.1	100
18	Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 97, 378-388.	1.1	100

#	ARTICLE	IF	CITATIONS
19	BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. <i>Current Medical Research and Opinion</i> , 2014, 30, 251-262.	1.9	99
20	Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS. <i>Neurology: Clinical Practice</i> , 2016, 6, 220-229.	1.6	91
21	Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 501-511.	3.0	86
22	T1&T2-weighted ratio differs in demyelinated cortex in multiple sclerosis. <i>Annals of Neurology</i> , 2017, 82, 635-639.	5.3	82
23	Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. <i>Neurology and Therapy</i> , 2015, 4, 93-104.	3.2	80
24	Clinically feasible MTR is sensitive to cortical demyelination in MS. <i>Neurology</i> , 2013, 80, 246-252.	1.1	79
25	Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1875-1883.	3.0	77
26	Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing&remitting multiple sclerosis: a systematic review and mixed treatment comparison. <i>Current Medical Research and Opinion</i> , 2014, 30, 613-627.	1.9	70
27	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing&remitting multiple sclerosis: subgroup analyses of the CONFIRM study. <i>Journal of Neurology</i> , 2013, 260, 2286-2296.	3.6	68
28	Effect of dimethyl fumarate on lymphocytes in RRMS. <i>Neurology</i> , 2019, 92, e1724-e1738.	1.1	66
29	Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. <i>Neurology</i> , 2015, 84, 1145-1152.	1.1	63
30	Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. <i>Contemporary Clinical Trials</i> , 2016, 50, 166-177.	1.8	59
31	Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing&remitting multiple sclerosis (RRMS). <i>Multiple Sclerosis Journal</i> , 2015, 21, 57-66.	3.0	56
32	Reassessing the risk of natalizumab-associated PML. <i>Journal of NeuroVirology</i> , 2016, 22, 533-535.	2.1	52
33	Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.. <i>Cleveland Clinic Journal of Medicine</i> , 2006, 73, 91-102.	1.3	52
34	Treatment of Susac syndrome with gamma globulin and corticosteroids. <i>Journal of the Neurological Sciences</i> , 2006, 251, 17-22.	0.6	50
35	Corrigendum. <i>Neurodegenerative Disease Management</i> , 2016, 6, 178-178.	2.2	50
36	Efficacy of delayed-release dimethyl fumarate in relapsing&remitting multiple sclerosis: integrated analysis of the phase 3 trials. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 103-118.	3.7	48

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 yearsâ€™ follow-up of DEFINE, CONFIRM, and ENDORSE. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642091500.	3.5	47
38	Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. <i>International Journal of MS Care</i> , 2015, 17, 236-243.	1.0	47
39	Picturing Multiple Sclerosis: Conventional and Diffusion Tensor Imaging. <i>Seminars in Neurology</i> , 2008, 28, 453-466.	1.4	46
40	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 44-52.	2.0	43
41	Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications. <i>Multiple Sclerosis Journal</i> , 2005, 11, 140-145.	3.0	41
42	Risk stratification and patient counseling for natalizumab in multiple sclerosis. <i>Neurology</i> , 2012, 78, 436-437.	1.1	41
43	Aphemia: an isolated disorder of articulation. <i>Clinical Neurology and Neurosurgery</i> , 2001, 103, 123-126.	1.4	40
44	New directions in MS therapeutics: vehicles of hope. <i>Trends in Immunology</i> , 2004, 25, 632-636.	6.8	40
45	Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsingâ€™remitting multiple sclerosis: findings from the CONFIRM study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 253-257.	3.0	40
46	Treatment Discontinuation and Disease Progression with Injectable Disease-Modifying Therapies. <i>International Journal of MS Care</i> , 2013, 15, 194-201.	1.0	37
47	Health Literacy Association With Health Behaviors and Health Care Utilization in Multiple Sclerosis: A Cross-Sectional Study. <i>Interactive Journal of Medical Research</i> , 2014, 3, e3.	1.4	37
48	Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. <i>Clinical Therapeutics</i> , 2014, 36, 1958-1971.	2.5	36
49	Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study. <i>Neurology and Therapy</i> , 2015, 4, 137-146.	3.2	36
50	Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis. <i>Drugs</i> , 2018, 78, 1549-1566.	10.9	36
51	Progressive MS: from pathophysiology to drug discovery. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1376-1384.	3.0	35
52	Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. <i>Current Medical Research and Opinion</i> , 2017, 33, 175-183.	1.9	34
53	Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsingâ€™Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. <i>Neurology and Therapy</i> , 2016, 5, 45-57.	3.2	33
54	Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	32

#	ARTICLE	IF	CITATIONS
55	A Preliminary Validation Study of Diffusion Tensor Imaging as a Measure of Functional Brain Injury. Archives of Neurology, 2008, 65, 1179-84.	4.5	31
56	Advanced MRI in Multiple Sclerosis: Current Status and Future Challenges. Neurologic Clinics, 2011, 29, 357-380.	1.8	31
57	Shared Decision Making and Autonomy Among US Participants with Multiple Sclerosis in the NARCOMS Registry. International Journal of MS Care, 2017, 19, 303-312.	1.0	30
58	The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments. Multiple Sclerosis and Related Disorders, 2019, 31, 165-172.	2.0	29
59	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731771548.	1.0	28
60	Scan-rescan repeatability and cross-scanner comparability of DTI metrics in healthy subjects in the SPRINT-MS multicenter trial. Magnetic Resonance Imaging, 2018, 53, 105-111.	1.8	28
61	Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2014-2022.	3.0	28
62	The window of opportunity for treatment of progressive multiple sclerosis. Current Opinion in Neurology, 2020, 33, 262-270.	3.6	27
63	Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study. Neurology, 2021, 96, e491-e500.	1.1	27
64	Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clinical Therapeutics, 2017, 39, 1671-1679.	2.5	26
65	Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Multiple Sclerosis Journal, 2022, 28, 801-816.	3.0	26
66	High hypothetical interest in physician-assisted death in multiple sclerosis. Neurology, 2017, 88, 1528-1534.	1.1	25
67	Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurology: Clinical Practice, 2018, 8, 292-301.	1.6	25
68	Perspectives on marijuana use and effectiveness. Neurology: Clinical Practice, 2017, 7, 333-343.	1.6	24
69	Landscape of MS patient cohorts and registries: Recommendations for maximizing impact. Multiple Sclerosis Journal, 2018, 24, 579-586.	3.0	24
70	Identifying the Start of Multiple Sclerosis Injury: A Serial DTI Study. Journal of Neuroimaging, 2014, 24, 569-576.	2.0	21
71	Risk tolerance to MS therapies: Survey results from the NARCOMS registry. Multiple Sclerosis and Related Disorders, 2015, 4, 241-249.	2.0	21
72	Measuring Brain Tissue Integrity during 4 Years Using Diffusion Tensor Imaging. American Journal of Neuroradiology, 2017, 38, 31-38.	2.4	20

#	ARTICLE	IF	CITATIONS
73	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years. Multiple Sclerosis Journal, 2022, 28, 1591-1605.	3.0	19
74	Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS. Neurology: Clinical Practice, 2016, 6, 397-408.	1.6	18
75	Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes. Multiple Sclerosis and Related Disorders, 2019, 29, 86-93.	2.0	18
76	Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI. Multiple Sclerosis Journal, 2022, 28, 198-205.	3.0	18
77	COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America. Neurology: Neuroimmunology and Neuroinflammation, 2021, 8, .	6.0	17
78	Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. Neurology: Clinical Practice, 2020, 10, 510-519.	1.6	17
79	Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM. Neurology and Therapy, 2017, 6, 175-187.	3.2	16
80	Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1564-1576.	3.0	16
81	Dimethyl Fumarate. International Journal of MS Care, 2017, 19, 74-83.	1.0	16
82	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. Multiple Sclerosis Journal, 2022, 28, 1526-1540.	3.0	16
83	Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance. Neurology, 2018, 90, 819-820.	1.1	15
84	Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. Journal of the Neurological Sciences, 2019, 407, 116498.	0.6	14
85	A survey of risk tolerance to multiple sclerosis therapies. Neurology, 2019, 92, e1634-e1642.	1.1	14
86	Quantitative quality assurance in a multicenter HARDI clinical trial at 3 T. Magnetic Resonance Imaging, 2017, 35, 81-90.	1.8	13
87	Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research, 2017, 6, 313-323.	1.4	13
88	Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies. Multiple Sclerosis Journal, 2020, 26, 1581-1589.	3.0	13
89	Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1384-1390.	3.0	13
90	Comprehensive Autopsy Program for Individuals with Multiple Sclerosis. Journal of Visualized Experiments, 2019, , .	0.3	12

#	ARTICLE	IF	CITATIONS
91	Technology-enabled assessments to enhance multiple sclerosis clinical care and research. <i>Neurology: Clinical Practice</i> , 2020, 10, 222-231.	1.6	12
92	NARCOMS and Other Registries in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2021, 23, 276-284.	1.0	12
93	Vitamin D and MRI measures in progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 276-282.	2.0	11
94	Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 742-754.	3.0	11
95	Current treatment options in multiple sclerosis. <i>Current Treatment Options in Neurology</i> , 2007, 9, 176-86.	1.8	10
96	Pseudobulbar affect. <i>Neurology: Clinical Practice</i> , 2018, 8, 472-481.	1.6	10
97	Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. <i>Clinical Therapeutics</i> , 2015, 37, 2543-2551.	2.5	9
98	Progressive multifocal leukoencephalopathy with extended natalizumab dosing. <i>Neurology: Clinical Practice</i> , 2018, 8, e12-e14.	1.6	9
99	In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: Yes. <i>Multiple Sclerosis Journal</i> , 2013, 19, 24-25.	3.0	8
100	Gender identity and sexual orientation affect health care satisfaction, but not utilization, in persons with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101440.	2.0	8
101	Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 111-118.	3.7	8
102	Progressive Multiple Sclerosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016, 22, 785-798.	0.8	8
103	Risk stratification and mitigation in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 639-649.	2.0	7
104	Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. <i>Journal of Neurology</i> , 2022, 269, 5093-5104.	3.6	7
105	A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 977-987.	3.7	7
106	Dimethyl fumarate for relapsing MS. <i>Neurology: Clinical Practice</i> , 2013, 3, 249-253.	1.6	6
107	Chronic Cerebrospinal Venous Insufficiency. <i>Journal of Ultrasound in Medicine</i> , 2015, 34, 1097-1106.	1.7	6
108	Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis. <i>International Journal of MS Care</i> , 2016, 18, 138-146.	1.0	6

#	ARTICLE	IF	CITATIONS
109	Autologous hematopoietic stem cell transplantation for MS. <i>Neurology</i> , 2017, 88, 2072-2073.	1.1	5
110	Technical Note: Retrospective reduction in systematic differences across scanner changes by accounting for noise floor effects in diffusion tensor imaging. <i>Medical Physics</i> , 2018, 45, 4171-4178.	3.0	5
111	Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1102-1110.	3.0	5
112	New applications for independent activities of daily living in measuring disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 97-106.	3.0	5
113	Juxtacortical susceptibility changes in progressive multifocal leukoencephalopathy at the grayâ€“white matter junction correlates with iron-enriched macrophages. <i>Multiple Sclerosis Journal</i> , 2021, 27, 135245852199965.	3.0	5
114	Vitamin D Levels and Visual System Measurements in Progressive Multiple Sclerosis. <i>International Journal of MS Care</i> , 2021, 23, 53-58.	1.0	5
115	Charting a global research strategy for progressive MSâ€“An international progressive MS Alliance proposal. <i>Multiple Sclerosis Journal</i> , 2022, 28, 16-28.	3.0	5
116	Multiple sclerosis: disease markers accelerate progress. <i>Lancet Neurology</i> , The, 2004, 3, 10.	10.2	4
117	Chronic cerebrospinal venous insufficiency: A Kuhnian paradigm shift or another fad?. <i>Cmaj</i> , 2011, 183, 1824-1825.	2.0	4
118	Correlating Function and Imaging Measures of the Medial Longitudinal Fasciculus. <i>PLoS ONE</i> , 2016, 11, e0147863.	2.5	4
119	Feast or famine in multiple sclerosis therapeutics. <i>Lancet Neurology</i> , The, 2020, 19, 196-197.	10.2	4
120	Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1781-1789.	3.0	4
121	Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732211020.	1.0	4
122	Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate. <i>International Journal of MS Care</i> , 2021, 23, 239-244.	1.0	3
123	Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression. <i>Neurology</i> , 2021, 97, 887-888.	1.1	3
124	COVID-19 in the pregnant or postpartum MS patient: Symptoms and outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 65, 104028.	2.0	3
125	MRI IN MULTIPLE SCLEROSIS. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2010, 16, 37-57.	0.8	2
126	Long-term registries. <i>Neurology: Clinical Practice</i> , 2016, 6, 97-99.	1.6	2

#	ARTICLE	IF	CITATIONS
127	Relationship between symptom change, relapse activity and disability progression in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 362, 121-126.	0.6	2
128	Importance of incorporating quantitative imaging biomarker technical performance characteristics when estimating treatment effects. <i>Clinical Trials</i> , 2021, 18, 197-206.	1.6	2
129	A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 96, 833-834.	1.1	2
130	DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity “ <i>Commentary. Multiple Sclerosis Journal</i> , 2022, 28, 187-188.	3.0	2
131	High-dose methylprednisolone to treat multiple sclerosis. , 0, , 418-435.		1
132	Multiple Sclerosis Treatment. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013, 19, 1092-1099.	0.8	1
133	Biomarkers for MS. <i>Neurology</i> , 2014, 83, 1488-1489.	1.1	1
134	Refining diagnosis of multiple sclerosis with revised MRI criteria. <i>Lancet Neurology</i> , The, 2016, 15, 238-240.	10.2	1
135	Demyelinating lesions and progressive MS. <i>Neurology</i> , 2019, 93, 283-284.	1.1	1
136	Fourteen-year serial MRIs of patients with mild and severe courses of MS. <i>Neurology: Clinical Practice</i> , 2020, 10, e5-e6.	1.6	1
137	Influence of equipment changes on MRI measures of brain atrophy and brain microstructure in a placebo-controlled trial of ibudilast in progressive multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110108.	1.0	1
138	How common is active inflammation in progressive multiple sclerosis?. <i>Nature Reviews Neurology</i> , 2021, 17, 463-464.	10.1	1
139	A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2021, 23, 245-252.	1.0	1
140	Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon- β ? <i>Nature Clinical Practice Neurology</i> , 2005, 1, 16-17.	2.5	0
141	Disability progression in relapsing MS is more than just lesions: The lesson of fingolimod. <i>Multiple Sclerosis Journal</i> , 2015, 21, 843-844.	3.0	0
142	Patient Perceptions of FDA Approval. <i>Neurology: Clinical Practice</i> , 2021, 11, 273-279.	1.6	0
143	Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 747853.	2.4	0